CALC
NASDAQCalciMedica Inc.
Price$0.73+0.14 (+22.70%)
2026-04-212026-07-24
News · 26 weeks34-11%
2026-02-012026-07-26
Mix2190d
- SEC Filings9(43%)
- Insider8(38%)
- Other3(14%)
- Offering1(5%)
Latest news
25 items- SECSEC Form S-3 filed by CalciMedica Inc.S-3 - CalciMedica, Inc. (0001534133) (Filer)
- SECSEC Form DEF 14A filed by CalciMedica Inc.DEF 14A - CalciMedica, Inc. (0001534133) (Filer)
- SECSEC Form PRE 14A filed by CalciMedica Inc.PRE 14A - CalciMedica, Inc. (0001534133) (Filer)
- INSIDERNew insider Alafi Capital Co Llc claimed ownership of 5,112,345 shares (SEC Form 3)3 - CalciMedica, Inc. (0001534133) (Issuer)
- SECSEC Form SCHEDULE 13D filed by CalciMedica Inc.SCHEDULE 13D - CalciMedica, Inc. (0001534133) (Subject)
- INSIDERSEC Form 4 filed by Director Zaytsev Evgeny4 - CalciMedica, Inc. (0001534133) (Issuer)
- INSIDERNew insider Zaytsev Evgeny claimed ownership of 2,113,513 shares (SEC Form 3)3 - CalciMedica, Inc. (0001534133) (Issuer)
- SECCalciMedica Inc. filed SEC Form 8-K: Leadership Update8-K - CalciMedica, Inc. (0001534133) (Filer)
- INSIDERCHIEF BUSINESS OFFICER Roberts Eric W was granted 186,729 shares, increasing direct ownership by 104% to 366,435 units (SEC Form 4)4 - CalciMedica, Inc. (0001534133) (Issuer)
- INSIDERDirector Wilson Robert N was granted 1,182,621 shares, increasing direct ownership by 280% to 1,604,650 units (SEC Form 4)4 - CalciMedica, Inc. (0001534133) (Issuer)
- INSIDERChief Medical Officer Hebbar Sudarshan was granted 124,486 shares, increasing direct ownership by 202% to 186,025 units (SEC Form 4)4 - CalciMedica, Inc. (0001534133) (Issuer)
- INSIDERCHIEF EXECUTIVE OFFICER Leheny A. Rachel was granted 186,729 shares, increasing direct ownership by 143% to 317,655 units (SEC Form 4)4 - CalciMedica, Inc. (0001534133) (Issuer)
- INSIDERDirector Middleton Fred A bought $199,999 worth of shares (248,972 units at $0.80) (SEC Form 4)4 - CalciMedica, Inc. (0001534133) (Issuer)
- SECCalciMedica Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure8-K - CalciMedica, Inc. (0001534133) (Filer)
- PRCalciMedica Announces Private Placement Financing for Up to Approximately $49 Million to Advance Pulmonary Hypertension ProgramProceeds expected to support a focused pulmonary hypertension strategy, including a Phase 1b proof-of-concept study evaluating Auxora™ in PAH, with data anticipated mid-2027, and advancement of oral CRAC channel inhibitor CM5480 to IND clearance expected mid-2027Anticipated cash runway into 2H 2027 with upfront proceedsLA JOLLA, Calif., June 24, 2026 /PRNewswire/ -- CalciMedica, Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today announced it has entered into a definitive securities purcha
- PRCalciMedica Announces Clinical Development of Auxora May Proceed Following FDA Review of KOURAGE Trial Interim Safety DataFDA reviewed a protocol amendment and interim safety data from the KOURAGE trial evaluating Auxora in AKI patientsNo comments or questions were receivedConfirms CalciMedica's ability to continue clinical development of Auxora across indicationsLA JOLLA, Calif., June 24, 2026 /PRNewswire/ -- CalciMedica, Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious inflammatory, immunologic, and cardiopulmonary diseases, today announced that the U.S. Food and Drug Administration (FDA) has reviewed a protocol amendment and interim safety data for CalciMedica's Ph
- SECCalciMedica Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Entry into a Material Definitive Agreement8-K - CalciMedica, Inc. (0001534133) (Filer)
- SECSEC Form 10-Q filed by CalciMedica Inc.10-Q - CalciMedica, Inc. (0001534133) (Filer)
- SECCalciMedica Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - CalciMedica, Inc. (0001534133) (Filer)
- PRCalciMedica Reports First Quarter 2026 Financial Results and Provides Clinical & Corporate UpdatesFDA feedback on the Auxora™ pivotal program in acute pancreatitis and potential future development in acute kidney injury expected in 2Q 2026 Preclinical and IND-enabling studies advancing for CM5480, an oral CRAC channel inhibitor candidate, with IND submission in pulmonary hypertension expected in 2027LA JOLLA, Calif., May 12, 2026 /PRNewswire/ -- CalciMedica Inc. ("CalciMedica" or the "Company") (NASDAQ:CALC), a clinical-stage biopharmaceutical company developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for serious acute and chronic inflammatory, immunologic, and cardiopulmonary diseases, today reported financial results for the first quarter ended March
- SECAmendment: SEC Form 10-K/A filed by CalciMedica Inc.10-K/A - CalciMedica, Inc. (0001534133) (Filer)
- INSIDERSEC Form 4 filed by Bardin Stephen4 - CalciMedica, Inc. (0001534133) (Issuer)
- INSIDERSEC Form 4 filed by Leheny A. Rachel4 - CalciMedica, Inc. (0001534133) (Issuer)
- INSIDERSEC Form 4 filed by Hebbar Sudarshan4 - CalciMedica, Inc. (0001534133) (Issuer)
- INSIDERSEC Form 4 filed by Stauderman Kenneth A.4 - CalciMedica, Inc. (0001534133) (Issuer)
CALC FAQ
6 questionsWhere does CALC stock trade?
CalciMedica Inc. (CALC) is listed on NASDAQ.What sector and industry is CALC in?
CalciMedica Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did CalciMedica Inc. go public?
CalciMedica Inc. (CALC) completed its IPO in 2023.What are analysts saying about CALC?
CalciMedica Inc. has had 1 recent analyst action on file. The most recent action was from H.C. Wainwright: Neutral on 2026-01-29.What companies are similar to CALC?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare CALC side-by-side with any of them on Quantisnow.How can I track CALC on Quantisnow?
Quantisnow aggregates CalciMedica Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow CALC to receive live email and push alerts on every new disclosure.